Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pirtobrutinib

FDA-approved product (tablet, oral), marketed as Jaypirca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pirtobrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pirtobrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pirtobrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    NCT06973187 · start 2025-09-04

    Registered record
    Registry ID
    NCT06973187
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Tacabrutideg; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-09-04
    Completion
    2028-04-17
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionTacabrutideg; Pirtobrutinib
    PhasePhase 3
    Registry statusRecruiting

  • Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

    NCT07162181 · start 2025-08-07

    Registered record
    Registry ID
    NCT07162181
    Conditions
    Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; B-cell Lymphoma
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-08-07
    Completion
    2030-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; B-cell Lymphoma
    InterventionPirtobrutinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    NCT07122609 · start 2025-08-05

    Registered record
    Registry ID
    NCT07122609
    Conditions
    Relapsed and Refractory DLBCL
    Interventions
    Pirtobrutinib; R-GemOx; Polatuzumab Vedotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-05
    Completion
    2027-08-15
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed and Refractory DLBCL
    InterventionPirtobrutinib; R-GemOx; Polatuzumab Vedotin
    PhasePhase 2
    Registry statusNot yet recruiting

  • Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

    NCT06967610 · start 2025-07-15

    Registered record
    Registry ID
    NCT06967610
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia (SLL)
    Interventions
    Pirtobrutinib; Venetoclax; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-15
    Completion
    2033-06-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Leukemia (SLL)
    InterventionPirtobrutinib; Venetoclax; Obinutuzumab
    PhasePhase 2
    Registry statusRecruiting

  • A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    NCT06876662 · start 2025-05-20

    Registered record
    Registry ID
    NCT06876662
    Conditions
    Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-20
    Completion
    2032-12
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
    InterventionPirtobrutinib
    PhasePhase 4
    Registry statusRecruiting

  • Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

    NCT06812715 · start 2025-05-05

    Registered record
    Registry ID
    NCT06812715
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2031-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionPirtobrutinib
    PhasePhase 2
    Registry statusRecruiting

  • LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

    NCT05990465 · start 2025-02-06

    Registered record
    Registry ID
    NCT05990465
    Conditions
    Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Burkitt Lymphoma
    Interventions
    Pirtobrutinib; LV20.19 CAR T cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-02-06
    Completion
    2030-07
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma +2 more
    InterventionPirtobrutinib; LV20.19 CAR T cells
    PhasePhase 1
    Registry statusRecruiting

  • A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT06588478 · start 2025-01-03

    Registered record
    Registry ID
    NCT06588478
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-01-03
    Completion
    2028-12
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib
    PhasePhase 2
    Registry statusRecruiting

  • Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

    NCT06466122 · start 2024-11-07

    Registered record
    Registry ID
    NCT06466122
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Pirtobrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-07
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

    NCT06553872 · start 2024-08-23

    Registered record
    Registry ID
    NCT06553872
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Pirtobrutinib; Brexucabtagene Autoleucel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-23
    Completion
    2029-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionPirtobrutinib; Brexucabtagene Autoleucel
    PhasePhase 2
    Registry statusRecruiting

  • Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

    NCT06252675 · start 2024-06-11

    Registered record
    Registry ID
    NCT06252675
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Obinutuzumab; Glofitamab; Pirtobrutinib; Tumor Imaging; Biospecimen Collection; ClonoSeq Assay; Bone Marrow Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-11
    Completion
    2028-07-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionObinutuzumab; Glofitamab; Pirtobrutinib; Tumor Imaging +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

    NCT06263491 · start 2024-05-29

    Registered record
    Registry ID
    NCT06263491
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Rituximab; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-29
    Completion
    2027-03-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionRituximab; Pirtobrutinib
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

    NCT06104683 · start 2024-05-01

    Registered record
    Registry ID
    NCT06104683
    Conditions
    Relapsing Multiple Sclerosis; Multiple Sclerosis
    Interventions
    Placebo; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-05-01
    Completion
    2026-02-13
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing Multiple Sclerosis; Multiple Sclerosis
    InterventionPlacebo; Pirtobrutinib
    PhasePhase 2
    Registry statusWithdrawn

  • Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

    NCT06333262 · start 2024-04-22

    Registered record
    Registry ID
    NCT06333262
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-22
    Completion
    2032-07-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Obinutuzumab
    PhasePhase 2
    Registry statusRecruiting

  • AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    NCT05602363 · start 2023-08-01

    Registered record
    Registry ID
    NCT05602363
    Conditions
    B-cell Malignancy; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma
    Interventions
    Docirbrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-08-01
    Completion
    2027-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Malignancy; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia +4 more
    InterventionDocirbrutinib
    PhasePhase 1
    Registry statusRecruiting